BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 2 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $149,017,898 | +82.4% | 5,651,039 | +19.0% | 0.91% | +98.9% |
| Q2 2023 | $81,688,700 | +40.3% | 4,749,343 | +35.2% | 0.46% | +15.4% |
| Q1 2023 | $58,241,544 | +243.8% | 3,512,759 | +58.0% | 0.40% | +401.3% |
| Q4 2022 | $16,941,196 | -15.8% | 2,223,254 | +9.8% | 0.08% | -33.6% |
| Q3 2022 | $20,125,000 | +50.3% | 2,024,640 | +37.3% | 0.12% | -42.5% |
| Q2 2022 | $13,388,000 | +89.5% | 1,474,450 | +111.9% | 0.21% | +140.7% |
| Q1 2022 | $7,064,000 | +2843.3% | 695,915 | +6113.5% | 0.09% | +4200.0% |
| Q3 2019 | $240,000 | -64.4% | 11,200 | -55.2% | 0.00% | -71.4% |
| Q2 2019 | $674,000 | – | 25,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $82,353,000 | 42.93% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $792,257,000 | 4.46% |
| Perceptive Advisors | 6,706,268 | $143,983,000 | 3.88% |
| Cormorant Asset Management, LP | 2,617,566 | $56,199,000 | 3.42% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $571,553,000 | 2.98% |
| SC US (TTGP), LTD. | 2,544,738 | $54,636,000 | 2.42% |
| HHLR ADVISORS, LTD. | 4,388,690 | $94,225,000 | 1.30% |
| Fernwood Investment Management, LLC | 95,200 | $2,044,000 | 1.01% |
| AMERICAN INTERNATIONAL GROUP, INC. | 6,746,511 | $144,847,000 | 0.58% |
| Ratan Capital Management LP | 46,548 | $999,000 | 0.53% |